

Real-world patient characteristics and treatment outcomes of
multiple myeloma patients who received Bortezomib in
combination with Dexamethasone as first line of therapy in the United States

BMC Cancer

22,

DOI: [10.1186/s12885-022-09980-9](https://doi.org/10.1186/s12885-022-09980-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature. <i>Cancers</i> , 2022, 14, 4741.	1.7	1
2	Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients. <i>Future Oncology</i> , 2022, 18, 3983-3991.	1.1	2
3	Eastern Cooperative Oncology Group, Î²2-microglobulin, hemoglobin, and lactate dehydrogenase can predict early gradeâ€” infection in patients with newly diagnosed multiple myeloma: A real-world multicenter study. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0